The question for biomanufacturing leaders is no longer whether to modernize their scientific data infrastructure, but how ...

Boltz-2 is the latest milestone in MIT Jameel Clinic’s growing portfolio of open-source tools for health, developed at the ...

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

Antibody-drug conjugates (ADCs) hit the scene in oncology many moons ago – in fact, this year marks 25 years since the first ...

Regulatory science also plays a crucial role in ensuring public trust in these products and facilitating the translation of ...

This episode of Chromatography Life takes a closer look at synthetic peptide drugs - one of the most compelling frontiers in biopharmaceutical analysis.

Minister – herald Remember Deketeke Herald Reporter The Government has called for urgent action to address mental health and substance abuse issues among children and youth, highlighting the threat ...

In the final segment of our three-part interview with Jon Bardsley of Thermo Fisher, Jon discusses mitigation strategies and ...

The funds will support Phase 2 testing of a drug the company believes to be able to safely home in on AMPA receptors, an ...

Vin Singh, Founder and CEO of BullFrog AI, commented, "Dr. Beltrán's featured participation in the XTalks webinar not only highlights our leadership position in AI-driven bioinformatics but also ...

Martin Vollmer, biopharma program manager at Agilent Technologies, spoke to LCGC International about the evolving importance of glucagon-like peptide-1 (GLP-1) therapeutics and the challenges they ...

Every disease area has its own unique challenges with respect to development and commercialisation of medicines that can make a difference to the lives of patients. The oncology space, in ...